Physician profile
Manish Suthar
NPI 1326123100
$3,756.82
in general payments reported to CMS, 2019-2025
35 companies · $549 in 2025
The $549 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $353 · 2021: $517 · 2022: $546 · 2023: $557 · 2024: $572 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.38 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $956.53 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $659.97 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $348.22 | 2019-2023 | Ztlido |
| Merck Sharp & Dohme LLC | $212.42 | 2020-2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $177.25 | 2019-2022 | |
| Eisai INC. | $161.92 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $144.22 | 2024-2025 | Horizant |
| Biodelivery Sciences International, INC. | $119.65 | 2019 | |
| Valinor Pharma, LLC | $100.70 | 2023-2025 | Movantik |
| Protega Pharmaceutials INC | $84.14 | 2024 | Roxybond |
| Pacira Therapeutics, INC. | $69.27 | 2019-2021 | |
| Depuy Synthes Sales INC. | $61.70 | 2019-2021 | |
| Orthogenrx INC. | $58.52 | 2019 | |
| Fidia Pharma USA INC. | $57.55 | 2021-2023 | Triluron, Hymovis |
| Zyla Life Sciences, INC. | $53.06 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $47.68 | 2023-2024 | Kloxxado, Ryaltris |
| Elite Orthopedics, LLC | $39.37 | 2020 | |
| Virtus Pharmaceuticals LLC | $38.17 | 2021 | |
| Allergan, INC. | $38.01 | 2021-2022 | |
| Daiichi Sankyo INC. | $34.57 | 2019 | |
| Bioventus LLC | $29.54 | 2021-2022 | |
| Pfizer INC. | $28.92 | 2019 | |
| Vertical Pharmaceuticals, LLC | $26.80 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $23.76 | 2025 | |
| Averitas Pharma INC. | $21.85 | 2024 | Qutenza |
| Biogen, INC. | $20.13 | 2021 | |
| Athena Bioscience, LLC | $18.96 | 2023 | Qdolo |
| Idorsia Pharmaceuticals US INC | $18.37 | 2023 | Quviviq |
| Globus Medical, INC. | $16.70 | 2025 | Senza |
| Kowa Pharmaceuticals America, INC. | $15.86 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.57 | 2019 | |
| Ibsa Pharma INC. | $15.50 | 2023 | Tirosint, Licart |
| Medtronic, INC. | $15.26 | 2023 | Intellis Adaptivestim |
| Assertio Therapeutics, INC. | $14.76 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Suthar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.